JO3438B1 - Aryl- or heteroaryl-substituted benzene compounds - Google Patents

Aryl- or heteroaryl-substituted benzene compounds

Info

Publication number
JO3438B1
JO3438B1 JOP/2018/0104A JOP20180104A JO3438B1 JO 3438 B1 JO3438 B1 JO 3438B1 JO P20180104 A JOP20180104 A JO P20180104A JO 3438 B1 JO3438 B1 JO 3438B1
Authority
JO
Jordan
Prior art keywords
heteroaryl
aryl
substituted benzene
benzene compounds
compounds
Prior art date
Application number
JOP/2018/0104A
Other languages
Arabic (ar)
Inventor
K Knutson Sarah
Natalie Warholic
Syuji Shirotori
Christine Klaus
Richard Chesworth
Kenneth William Duncan
Kevin Wayne Kuntz
Masashi Seki
Heike Keilhack
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045109&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3438(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of JOP20180104A1 publication Critical patent/JOP20180104A1/en
Application granted granted Critical
Publication of JO3438B1 publication Critical patent/JO3438B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof.
JOP/2018/0104A 2011-04-13 2011-04-13 Aryl- or heteroaryl-substituted benzene compounds JO3438B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474821P 2011-04-13 2011-04-13
US201161499595P 2011-06-21 2011-06-21

Publications (2)

Publication Number Publication Date
JOP20180104A1 JOP20180104A1 (en) 2019-01-30
JO3438B1 true JO3438B1 (en) 2019-10-20

Family

ID=46045109

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2018/0104A JO3438B1 (en) 2011-04-13 2011-04-13 Aryl- or heteroaryl-substituted benzene compounds
JOP/2012/0087A JO3363B1 (en) 2011-04-13 2012-04-10 Aryl- or heteroaryl-substituted benzene compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2012/0087A JO3363B1 (en) 2011-04-13 2012-04-10 Aryl- or heteroaryl-substituted benzene compounds

Country Status (36)

Country Link
US (11) US8410088B2 (en)
EP (4) EP3943485B1 (en)
JP (6) JP5933686B2 (en)
KR (7) KR102308488B1 (en)
CN (2) CN104080769B (en)
AR (1) AR086008A1 (en)
AU (1) AU2012242595B2 (en)
BR (2) BR112013026324B1 (en)
CA (2) CA2832843C (en)
CL (1) CL2013002898A1 (en)
CY (3) CY1117986T1 (en)
DK (4) DK3150580T3 (en)
ES (3) ES2886099T3 (en)
FI (1) FI3943485T3 (en)
HK (1) HK1193804A1 (en)
HR (3) HRP20211297T8 (en)
HU (3) HUE028837T2 (en)
IL (3) IL228745A (en)
JO (2) JO3438B1 (en)
LT (4) LT3486234T (en)
ME (1) ME02500B (en)
MX (2) MX343685B (en)
MY (1) MY166171A (en)
NZ (3) NZ734744A (en)
PE (1) PE20140863A1 (en)
PH (1) PH12016502132A1 (en)
PL (3) PL2697199T3 (en)
PT (4) PT3150580T (en)
RS (3) RS62279B1 (en)
RU (1) RU2632193C2 (en)
SG (1) SG194447A1 (en)
SI (3) SI3150580T1 (en)
SM (1) SMT201600308B (en)
TW (1) TWI529162B (en)
WO (1) WO2012142504A1 (en)
ZA (1) ZA201307539B (en)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
RU2618475C2 (en) 2010-09-10 2017-05-03 Эпизайм, Инк. Human ezh2 inhibitors and methods of application thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JO3438B1 (en) * 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TW201733984A (en) * 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
BR112014007603A2 (en) * 2011-09-30 2017-06-13 Glaxosmithkline Llc cancer treatment methods
WO2013075084A1 (en) 2011-11-18 2013-05-23 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
TR201904660T4 (en) * 2012-03-12 2019-05-21 Epizyme Inc Human EZH2 inhibitors and methods of use.
IL289300B1 (en) * 2012-04-13 2024-01-01 Epizyme Inc Combination therapy for treating cancer
DK2836491T3 (en) * 2012-04-13 2017-03-06 Epizyme Inc SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
JP6254169B2 (en) * 2012-09-28 2017-12-27 ファイザー・インク Benzamide and heterobenzamide compounds
HUE046790T2 (en) * 2012-10-15 2020-03-30 Epizyme Inc Methods of treating cancer
KR102057365B1 (en) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 Substituted benzene compounds
KR20150095779A (en) * 2012-12-13 2015-08-21 글락소스미스클라인 엘엘씨 Enhancer of zeste homolog 2 inhibitors
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
CA2894216A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
UA111305C2 (en) 2012-12-21 2016-04-11 Пфайзер Інк. Condensed with lactams of aryl and heteroaryl
PE20160044A1 (en) * 2013-02-11 2016-02-11 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS THAT INCLUDE THEM AND THEIR USES
WO2014178954A1 (en) 2013-03-14 2014-11-06 Epizyme, Inc. Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9133189B2 (en) 2013-03-14 2015-09-15 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153235A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153100A2 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
US9447079B2 (en) 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
CN105339351B (en) 2013-03-14 2018-11-06 Epizyme股份有限公司 Arginine methyltransferase inhibitor and application thereof
US9023883B2 (en) 2013-03-14 2015-05-05 Epizyme, Inc. PRMT1 inhibitors and uses thereof
BR112015022604A2 (en) 2013-03-14 2017-10-24 Genentech Inc Uses of a Chromatin Modifier Modulator and an Egfr Antagonist
EP2970181B1 (en) 2013-03-14 2017-06-07 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
WO2014153090A1 (en) 2013-03-14 2014-09-25 Epizyme, Inc. Pyrazole derivatives asprmt1 inhibitors and uses thereof
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9243001B2 (en) 2013-03-15 2016-01-26 Epizyme, Inc. Substituted benzene compounds
WO2014172044A1 (en) 2013-03-15 2014-10-23 Epizyme, Inc. Substituted benzene compounds
KR20160003115A (en) 2013-04-30 2016-01-08 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Enhancer of zeste homolog 2 inhibitors
JP2016520645A (en) * 2013-06-06 2016-07-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｎｏ．２ Ｌｉｍｉｔｅｄ ZESTE homolog 2 enhancer inhibitor
CA2917463A1 (en) * 2013-07-10 2015-01-15 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
WO2015010049A1 (en) * 2013-07-19 2015-01-22 Epizyme, Inc. Substituted benzene compounds
WO2015010078A2 (en) 2013-07-19 2015-01-22 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
FI3057962T3 (en) * 2013-10-16 2023-11-03 Epizyme Inc Hydrochloride salt form for ezh2 inhibition
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
CN105873592B (en) * 2013-12-06 2023-01-31 Epizyme股份有限公司 Combination therapy for the treatment of cancer
CN105037360B (en) * 2014-04-28 2016-08-17 四川大学 Pyridione derivatives and its production and use
PT3157527T (en) 2014-06-17 2023-06-30 Eisai R&D Man Co Ltd Ezh2 inhibitors for treating lymphoma
GEP20186933B (en) 2014-06-17 2018-12-10 Pfizer Substituted dihydroisoquinoline compounds
WO2015200650A1 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Substituted benzene and 6,5-fused bicyclic heteroaryl compounds
MX2021007003A (en) 2014-10-16 2022-08-09 Epizyme Inc Method for treating cancer.
MA40848A (en) * 2014-10-28 2021-05-05 Glaxosmithkline Ip No 2 Ltd EZH2 INHIBITORS (ENHANCER OF ZESTE HOMOLOG 2)
BR112017009671A2 (en) 2014-11-06 2017-12-26 Dana Farber Cancer Inst Inc ezh2 inhibitors and uses of these
IL296080B2 (en) 2014-11-17 2023-12-01 Eisai R&D Man Co Ltd Method for treating cancer
AR102767A1 (en) 2014-12-05 2017-03-22 Lilly Co Eli EZH2 INHIBITORS
EA201792304A1 (en) * 2015-04-20 2018-03-30 Эпизайм, Инк. COMBINED THERAPY FOR CANCER TREATMENT
EA201890009A1 (en) 2015-06-10 2018-07-31 Эпизайм, Инк. EZH2 INHIBITORS FOR TREATING LYMPHOMA
TW201708210A (en) * 2015-06-30 2017-03-01 葛蘭素史克智慧財產（第二）有限公司 Enhancer of ZESTE homolog 2 inhibitors
MX2018002344A (en) 2015-08-24 2018-07-06 Epizyme Inc Method for treating cancer.
TW201718598A (en) 2015-08-27 2017-06-01 美國禮來大藥廠 Inhibitors of EZH2
WO2017040190A1 (en) 2015-08-28 2017-03-09 Constellation Pharmaceuticals, Inc. Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
MX2018004132A (en) 2015-10-06 2018-09-26 Epizyme Inc Method of treating medulloblastoma with an ezh2 inhibitor.
EP3370725A4 (en) * 2015-11-06 2019-07-03 Epizyme, Inc. Pediatric dosing for treatment of cancer with an ezh2 inhibitor
AU2016357900B2 (en) 2015-11-19 2020-09-17 Jiangsu Hengrui Medicine Co., Ltd. Benzofuran derivative, preparation method thereof and use thereof in medicine
CN105440023A (en) * 2015-12-10 2016-03-30 江苏理工学院 Synthetic method of EPZ-6438
TWI773657B (en) 2015-12-18 2022-08-11 美商亞德利克斯公司 Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists
JP2019503391A (en) * 2016-01-29 2019-02-07 エピザイム，インコーポレイティド Combination therapy to treat cancer
KR20230042756A (en) 2016-03-15 2023-03-29 오리존 지노믹스 에스.에이. Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017174023A1 (en) * 2016-04-08 2017-10-12 南京明德新药研发股份有限公司 Biphenyl compound serving as ezh2 inhibitor
WO2017184999A1 (en) * 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Ezh2 inhibitors and uses thereof
US10987353B2 (en) 2016-05-04 2021-04-27 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and platinum-based antineoplastic drugs
JP2019516685A (en) 2016-05-05 2019-06-20 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ Enhancer of ZESTE Homolog 2 Inhibitor
AU2017273726B2 (en) 2016-06-01 2023-10-19 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
US11147819B2 (en) 2016-06-17 2021-10-19 Epizyme, Inc. EZH2 inhibitors for treating cancer
CA3039059A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
US20200078362A1 (en) 2016-12-02 2020-03-12 Epizyme, Inc. Combination therapy for treating cancer
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
CN108314677B (en) 2017-01-17 2020-06-30 安徽中科拓苒药物科学研究有限公司 EZH2 inhibitor and application thereof
TW201831181A (en) * 2017-01-19 2018-09-01 日商第一三共股份有限公司 Therapeutic agent for htlv-1-associated myelopathy
US11214561B2 (en) 2017-01-25 2022-01-04 Ancureall Pharmaceutical (Shanghai) Co., Ltd. Histone methyltransferase EZH2 inhibitor, preparation method and pharmaceutical use thereof
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
WO2018195450A1 (en) * 2017-04-21 2018-10-25 Epizyme, Inc. Combination therapies with ehmt2 inhibitors
AU2018269268B2 (en) 2017-05-18 2022-01-06 Jiangsu Hengrui Medicine Co., Ltd. Crystal of benzofuran derivative free base and preparation method
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
US20230201212A1 (en) 2017-06-13 2023-06-29 Epizyme, Inc. Inhibitors of ezh2 and methods of use thereof
JP7399079B2 (en) * 2017-09-05 2023-12-15 エピザイム，インコーポレイティド Combination therapy to treat cancer
RU2754131C1 (en) 2017-11-14 2021-08-27 Пфайзер Инк. Combined therapy with ezh2 inhibitor
EP4043466A1 (en) 2018-01-31 2022-08-17 Mirati Therapeutics, Inc. Prc2 inhibitors
CN108640842B (en) * 2018-04-04 2021-06-04 大连九信精细化工有限公司 Synthetic method of 2-bromo-5-fluoronitrobenzene
MX2020013117A (en) * 2018-06-07 2021-02-18 Merck Sharp & Dohme Llc Processes for the preparation of sugammadex.
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
WO2020020374A1 (en) * 2018-07-27 2020-01-30 苏州信诺维医药科技有限公司 Polysubstituted benzene compound and preparation method and use thereof
KR20200101219A (en) 2019-02-19 2020-08-27 한미약품 주식회사 Novel heterotricyclic derivatives and use thereof
US20220024941A1 (en) * 2019-03-25 2022-01-27 Shanghai Synergy Pharmaceutical Sciences Co., Ltd. Preparation Method for Amide Compounds and Use Thereof in Medical Field
CN114555112A (en) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 Combination therapy of T cell therapy and ZESTE enhancer homolog 2(EZH2) inhibitors and related methods
WO2021249305A1 (en) * 2020-06-08 2021-12-16 南京明德新药研发有限公司 Biphenyl compound
JP2023545165A (en) * 2020-10-13 2023-10-26 エボポイント、バイオサイエンシズ、カンパニー、リミテッド Crystal form of polysubstituted benzene ring compound maleate, its preparation method and its uses
CN114907300A (en) * 2021-02-08 2022-08-16 上海医药工业研究院 Preparation method of taraxestat key intermediate and intermediate thereof
CN114907299A (en) * 2021-02-08 2022-08-16 上海医药工业研究院 Novel salt form of tarezostat key intermediate, preparation method thereof and intermediate thereof
CN113292489B (en) * 2021-06-16 2022-08-30 泓博智源(开原)药业有限公司 Preparation method of dichlorodialkyl nicotinonitrile
CN113527275A (en) * 2021-07-20 2021-10-22 成都师范学院 SKLB1039 compound and preparation method and application thereof
CN113582863B (en) * 2021-08-19 2023-05-26 沈阳农业大学 Aminoethyl biphenyl compound and preparation method and application thereof
KR20230081459A (en) 2021-11-30 2023-06-07 엘젠테라퓨틱스 주식회사 Novel 3-pyridine and 4-phenylpyridine derivatives substituted with heterocyclics and uses thereof
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
TW202400140A (en) 2022-04-27 2024-01-01 日商第一三共股份有限公司 Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor
WO2023244918A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
CN115197202B (en) * 2022-07-15 2024-01-26 四川大学 EZH2 covalent inhibitor and preparation method and application thereof

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPH0733729A (en) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Production of n-cyano-n'-substituted-arylcarboxyimidamide compound
CA2155662A1 (en) 1993-12-27 1995-07-06 Fumihiro Ozaki Anthranilic acid derivative
DE19516776A1 (en) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin regulatory genes
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
US5763263A (en) 1995-11-27 1998-06-09 Dehlinger; Peter J. Method and apparatus for producing position addressable combinatorial libraries
JP3906935B2 (en) 1995-12-18 2007-04-18 杏林製薬株式会社 N-substituted dioxothiazolidylbenzamide derivative and process for producing the same
JP2002525352A (en) 1998-09-30 2002-08-13 ザ、プロクター、エンド、ギャンブル、カンパニー 2-substituted ketoamide
UA71587C2 (en) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Anthranilic acid amides and use thereof as medicaments
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
BR0116539A (en) 2000-12-28 2003-09-23 Shionogi & Co Pyridone derivatives having a cannabinoid receptor 2 binding activity
CA2436487A1 (en) * 2001-01-30 2002-08-08 Cytopia Pty Ltd. Methods of inhibiting kinases
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
CA2469435A1 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulators of lxr
AU2003211442A1 (en) 2002-02-19 2003-09-09 Shionogi And Co., Ltd. Antipruritics
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
WO2004060377A1 (en) 2002-12-27 2004-07-22 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
DK2476667T3 (en) 2003-02-26 2014-09-15 Sugen Inc Amino heteroaryl compounds as protein kinase inhibitors
WO2005014599A1 (en) * 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
ES2374272T3 (en) 2003-06-19 2012-02-15 Glaxosmithkline Llc DERIVATIVES OF 5- (ACILAMINE) INDAZOL AS QUINASE INHIBITORS.
CL2004001834A1 (en) * 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp COMPOUND 4- {4- [3- (4-CHLORO-3-TRIFLUOROMETILFENIL) -UREIDO] -3-FLUOROFENOXI} -PIRIDIN-2-METHYLAMIDE, RAF INHIBITOR, VEGFR, P38 AND PDGFR KINASES, ITS SALTS; PHARMACEUTICAL COMPOSIICON; PHARMACEUTICAL COMBINATION; AND ITS USE TO TREAT HYPERPROL DISORDERS
BRPI0413826A (en) 2003-08-26 2006-10-24 Aton Pharma Inc process of treating cancer with hdac inhibitors
US20050059682A1 (en) 2003-09-12 2005-03-17 Supergen, Inc., A Delaware Corporation Compositions and methods for treatment of cancer
BRPI0508579A (en) 2004-03-11 2007-08-14 Actelion Pharmaceuticals Ltd compound, pharmaceutical composition, and use of a compound
CN1286973C (en) 2004-04-12 2006-11-29 上海第二医科大学附属瑞金医院 Histone methyl transferase and its preparing method
JP5160885B2 (en) 2004-06-01 2013-03-13 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル Reconstituted histone methyltransferase complex and method for identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
ATE494548T1 (en) 2005-06-02 2011-01-15 Univ North Carolina PURIFICATION, CHARACTERIZATION AND RECOVERY OF A UBIQUITIN E3 LIGASE
FR2889526B1 (en) 2005-08-04 2012-02-17 Aventis Pharma Sa SUBSTITUTED 7-AZA-INDAZOLES, COMPOSITIONS CONTAINING SAME, PROCESS FOR PRODUCTION AND USE
NZ593684A (en) 2005-10-19 2012-11-30 Gruenenthal Chemie Novel vanilloid receptor ligands and their use for producing medicaments
ATE510822T1 (en) 2005-10-21 2011-06-15 Merck Sharp & Dohme POTASSIUM CHANNEL INHIBITORS
US20090203057A1 (en) 2005-10-28 2009-08-13 Yi Zhang Protein demethylases comprising a jmjc domain
EP1960551A2 (en) 2005-12-01 2008-08-27 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
AU2006325746A1 (en) 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2730661A1 (en) 2006-01-20 2014-05-14 The University of North Carolina at Chapel Hill Diagnostic and therapeutic targets for leukemia
CA2650329A1 (en) 2006-05-15 2008-06-19 Irm Llc Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
EP2114898A2 (en) * 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2008104077A1 (en) 2007-02-28 2008-09-04 Methylgene Inc. Small molecule inhibitors of protein arginine methyltransferases (prmts)
WO2008109534A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting ezh2 gene expression and uses thereof
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (en) 2007-04-13 2008-10-16 Grünethal GmbH Novel vanilloid receptor ligands and their use in the preparation of medicines
US20090012031A1 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
CN101754955A (en) 2007-07-16 2010-06-23 雅培制药有限公司 Indazole, benzisoxa azoles and benzisothia azole compounds as kinases inhibitor
CA2703909A1 (en) * 2007-10-31 2009-05-07 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
WO2009077766A1 (en) 2007-12-19 2009-06-25 Cancer Research Technology Limited Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009094427A1 (en) 2008-01-23 2009-07-30 Bristol-Myers Squibb Company 4-pyridinone compounds and their use for cancer
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
UY31982A (en) * 2008-07-16 2010-02-26 Boehringer Ingelheim Int DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED
CA2730064A1 (en) 2008-08-08 2010-02-11 Asim Kumar Debnath Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (en) 2008-08-14 2010-08-27 Sanofi Aventis POLYSUBSTITUTED AZETIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
MX2011010062A (en) * 2009-03-24 2011-11-18 Sanofi Sa 9h-pyrrolo[2,3-b: 5,4-c'] dipyridine azacarboline derivatives, preparation thereof, and therapeutic use thereof.
EP2411007A4 (en) 2009-03-27 2012-12-05 Uab Research Foundation Modulating ires-mediated translation
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
US8329149B2 (en) 2009-12-30 2012-12-11 Avon Products, Inc. Topical lightening composition and uses thereof
EP2566479B1 (en) * 2010-05-07 2014-12-24 GlaxoSmithKline LLC Azaindazoles
JP5864546B2 (en) * 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ Indazole
MX2012012966A (en) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
RU2618475C2 (en) 2010-09-10 2017-05-03 Эпизайм, Инк. Human ezh2 inhibitors and methods of application thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (en) 2011-04-13 2019-10-20 Epizyme Inc Aryl- or heteroaryl-substituted benzene compounds
TW201733984A (en) * 2011-04-13 2017-10-01 雅酶股份有限公司 Substituted benzene compounds
BR112014007603A2 (en) 2011-09-30 2017-06-13 Glaxosmithkline Llc cancer treatment methods
TR201904660T4 (en) * 2012-03-12 2019-05-21 Epizyme Inc Human EZH2 inhibitors and methods of use.
DK2836491T3 (en) 2012-04-13 2017-03-06 Epizyme Inc SALT FORM OF A HUMAN HISTONMETHYL TRANSFERASE EZH2 INHIBITOR
IL289300B1 (en) 2012-04-13 2024-01-01 Epizyme Inc Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
HUE046790T2 (en) 2012-10-15 2020-03-30 Epizyme Inc Methods of treating cancer
KR102057365B1 (en) 2012-10-15 2019-12-18 에피자임, 인코포레이티드 Substituted benzene compounds

Also Published As

Publication number Publication date
KR20190121386A (en) 2019-10-25
EP2697199B1 (en) 2016-06-08
EP3486234B1 (en) 2021-06-02
PH12016502132A1 (en) 2017-05-22
DK3150580T3 (en) 2019-02-04
US20150353494A1 (en) 2015-12-10
IL249273A0 (en) 2017-01-31
CA2832843C (en) 2020-09-29
NZ717119A (en) 2017-10-27
PT3486234T (en) 2021-09-07
SI3150580T1 (en) 2019-03-29
KR102566864B1 (en) 2023-08-11
PL3150580T3 (en) 2019-04-30
HRP20190074T1 (en) 2019-03-08
JP2023011933A (en) 2023-01-24
EP3943485A1 (en) 2022-01-26
CN107311921B (en) 2021-02-12
EP3150580B1 (en) 2018-10-17
KR20230134128A (en) 2023-09-20
KR102154946B1 (en) 2020-09-10
US10155002B2 (en) 2018-12-18
LT3150580T (en) 2019-02-11
JO3363B1 (en) 2019-03-13
KR101955871B1 (en) 2019-03-08
US20170252349A1 (en) 2017-09-07
HUE042788T2 (en) 2019-07-29
US9549931B2 (en) 2017-01-24
HK1193804A1 (en) 2014-10-03
IL266418A (en) 2019-06-30
JP2021042243A (en) 2021-03-18
MY166171A (en) 2018-06-07
PL2697199T3 (en) 2016-12-30
US20140288041A1 (en) 2014-09-25
CL2013002898A1 (en) 2014-08-22
EP3486234A1 (en) 2019-05-22
IL228745A (en) 2016-12-29
BR112013026324A2 (en) 2016-10-11
ES2706951T3 (en) 2019-04-01
RS58226B1 (en) 2019-03-29
TWI529162B (en) 2016-04-11
RU2013150345A (en) 2015-05-20
CY1117986T1 (en) 2017-05-17
HUE028837T2 (en) 2017-01-30
BR122020006541B1 (en) 2022-05-10
MX343685B (en) 2016-11-17
LT2697199T (en) 2016-09-26
SMT201600308B (en) 2016-11-10
US20200155562A1 (en) 2020-05-21
ES2589555T3 (en) 2016-11-15
KR20200105543A (en) 2020-09-07
HRP20211297T1 (en) 2021-12-10
PT3150580T (en) 2019-01-28
SI3486234T1 (en) 2021-12-31
US9855275B2 (en) 2018-01-02
PT2697199T (en) 2016-09-05
KR20140029442A (en) 2014-03-10
EP2697199A1 (en) 2014-02-19
US20170119780A1 (en) 2017-05-04
HUE056552T2 (en) 2022-02-28
PE20140863A1 (en) 2014-07-19
JP2018104450A (en) 2018-07-05
DK2697199T3 (en) 2016-09-12
US20120264734A1 (en) 2012-10-18
US9090562B2 (en) 2015-07-28
WO2012142504A1 (en) 2012-10-18
EP3150580A1 (en) 2017-04-05
RU2017132054A (en) 2019-02-06
RU2017132054A3 (en) 2021-05-14
US20190192526A1 (en) 2019-06-27
AR086008A1 (en) 2013-11-13
JOP20180104A1 (en) 2019-01-30
AU2012242595B2 (en) 2014-05-15
BR112013026324B1 (en) 2020-12-08
RS55113B1 (en) 2016-12-30
US11052093B2 (en) 2021-07-06
DK3486234T3 (en) 2021-08-16
US20130123234A1 (en) 2013-05-16
RS62279B1 (en) 2021-09-30
KR101914321B1 (en) 2018-11-02
JP2014516931A (en) 2014-07-17
FI3943485T3 (en) 2024-01-29
MX2013011921A (en) 2014-03-27
ME02500B (en) 2017-02-20
JP6778226B2 (en) 2020-10-28
KR102032303B1 (en) 2019-10-15
LT3943485T (en) 2024-02-12
CY1124617T1 (en) 2022-07-22
US8410088B2 (en) 2013-04-02
TW201302704A (en) 2013-01-16
RU2632193C2 (en) 2017-10-03
DK3943485T3 (en) 2024-01-22
IL249273B (en) 2019-05-30
CY1121120T1 (en) 2019-12-11
KR20190025055A (en) 2019-03-08
US20160022693A1 (en) 2016-01-28
JP2016147886A (en) 2016-08-18
KR20180120275A (en) 2018-11-05
JP5933686B2 (en) 2016-06-15
US8765732B2 (en) 2014-07-01
US20180318309A1 (en) 2018-11-08
MX2020012695A (en) 2021-04-12
EP3943485B1 (en) 2023-12-27
NZ616298A (en) 2016-03-31
US20210379076A1 (en) 2021-12-09
SI2697199T1 (en) 2016-10-28
CA2832843A1 (en) 2012-10-18
ZA201307539B (en) 2014-06-25
ES2886099T3 (en) 2021-12-16
KR20210118968A (en) 2021-10-01
HRP20161115T1 (en) 2016-11-18
NZ734744A (en) 2019-03-29
US9522152B2 (en) 2016-12-20
US10420775B2 (en) 2019-09-24
CN104080769A (en) 2014-10-01
CN107311921A (en) 2017-11-03
PT3943485T (en) 2024-03-06
CN104080769B (en) 2017-06-20
LT3486234T (en) 2021-09-10
BR112013026324A8 (en) 2018-01-30
AU2012242595A1 (en) 2013-05-02
CA3086473A1 (en) 2012-10-18
KR102308488B1 (en) 2021-10-06
JP2019014732A (en) 2019-01-31
HRP20211297T8 (en) 2022-02-18
IL228745A0 (en) 2013-12-31
SG194447A1 (en) 2013-12-30
PL3486234T3 (en) 2021-11-29

Similar Documents

Publication Publication Date Title
PH12016502132A1 (en) Aryl-or heteroaryl-substituted benzene compounds
MX2013011922A (en) Substituted benzene compounds.
PH12015500825B1 (en) Substituted benzene compounds
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
MX2020010535A (en) Methods of treating cancer.
TN2015000278A1 (en) Autotaxin inhibitors
IN2014MN00986A (en)
IN2014MN00948A (en)
UA109464C2 (en) Spiro-oxindoles as mdm2 antagonists
IN2012MN02591A (en)
MX349004B (en) New compounds.
MX346375B (en) Spiro-oxindole mdm2 antagonists.
IN2014MN00988A (en)
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
MX342924B (en) Novel disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases.
IN2015DN02109A (en)
UA110969C2 (en) Aryl- or heteroaryl substituted benzene compounds and pharmaceutical compositions based thereon
TN2013000202A1 (en) Spiro-oxindole mdm2 antagonists
MX2012007471A (en) Substituted pyrrolo-aminopyrimidine compounds.